Press release
Rising Tobacco Consumption Fuels Growth In The Non-Small Cell Lung Cancer (NSCLC) Market Driver: A Major Catalyst in the Evolution of the Non-Small Cell Lung Cancer (NSCLC) Market in 2025
Non Small Cell Lung Cancer NSCLC Market Report
The non-small cell lung cancer (NSCLC) market has seen rapid growth in recent years. It is projected to increase from $20.1 billion in 2024 to $22.35 billion in 2025, reflecting a CAGR of 11.1%. The historical growth can be linked to advancements in immunotherapy, the adoption of genomic profiling and precision medicine, the expansion of clinical trials, and efforts to reduce smoking rates.
The non-small cell lung cancer (NSCLC) market is expected to grow rapidly, reaching $33.29 billion by 2029 at a CAGR of 10.5%. This growth is driven by emerging combination therapies, AI integration, expansion of personalized vaccines, global research collaborations, and patient-centric care. Key trends include the integration of telemedicine in oncology, the use of liquid biopsy technologies, advances in diagnostic technologies, minimally invasive surgical techniques, and the adoption of immune checkpoint inhibitors.
What Are the Key Drivers Behind the Growth of the Non-Small Cell Lung Cancer (NSCLC) Market?
The growing rate of tobacco consumption is expected to stimulate the expansion of the non-small cell lung cancer (NSCLC) market in the future. Tobacco consumption involves the use of tobacco products through smoking, chewing, or snuffing, introducing nicotine and various harmful chemicals into the body. Tobacco smoke contains carcinogens that can damage lung cell DNA, causing mutations that contribute to the uncontrolled growth of cancerous cells, including NSCLC. For instance, in October 2024, the 2024 National Youth Tobacco Survey, published by the US Food and Drug Administration (USFDA), a US-based federal agency, revealed that 1.1% of all students (approximately 2.25 million) reported using tobacco products, with 10.1% of high school students (about 1.58 million) and 5.4% of middle school students (around 640,000) engaging in tobacco consumption. Furthermore, 2.8% of students (approximately 760,000) reported using combustible tobacco products, while 3.0% (roughly 840,000) admitted to using multiple tobacco products. Consequently, the increasing tobacco consumption rate is driving the growth of the non-small cell lung cancer (NSCLC) market.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp
Who Are the Major Industry Players Fueling Non-Small Cell Lung Cancer (NSCLC) Market Expansion?
Major companies operating in the non-small cell lung cancer (NSCLC) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines
Which Key Developments Are Influencing the Non-Small Cell Lung Cancer (NSCLC) Market?
Key players in the non-small cell lung cancer (NSCLC) market are developing various treatment strategies, including monotherapy treatments, to gain a competitive advantage. Monotherapy refers to the use of a single drug or therapy to treat a medical condition, rather than a combination of multiple treatments. For instance, in June 2022, Novartis AG, a Switzerland-based pharmaceutical company, received approval from the European Commission (EC), a governing body in Belgium, for Tabrecta (capmatinib) to treat adult patients with advanced non-small cell lung cancer exhibiting METex14 skipping mutations. This approval introduces a novel targeted therapy option for patients in Europe who have previously undergone treatment and have advanced NSCLC with MET exon 14 (METex14) skipping mutations. Tabrecta is a prominent targeted treatment for advanced NSCLC, addressing genetic modifications related to METex14 skipping.
How Is the Segmentation of the Non-Small Cell Lung Cancer (NSCLC) Market Defined?
The non-small cell lung cancer (NSCLC) market covered in this report is segmented -
1) By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types
2) By Therapy: Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Other Therapies
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels
Subsegments:
1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma
2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma, Large Cell Neuroendocrine Carcinoma
3) By Adenocarcinoma: Invasive Adenocarcinoma, Bronchioloalveolar Carcinoma
4) By Other Types: Mixed Cell Type Carcinoma, Sarcomatoid Carcinoma
Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report
What Is the Leading Region in the Non-Small Cell Lung Cancer (NSCLC) Market?
North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (NSCLC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Is Covered In The Non-Small Cell Lung Cancer (NSCLC) Global Market Report?
- Market Size Analysis: Analyze the Non-Small Cell Lung Cancer (NSCLC) Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Non-Small Cell Lung Cancer (NSCLC) Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Non-Small Cell Lung Cancer (NSCLC) Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Non-Small Cell Lung Cancer (NSCLC) Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13232
Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rising Tobacco Consumption Fuels Growth In The Non-Small Cell Lung Cancer (NSCLC) Market Driver: A Major Catalyst in the Evolution of the Non-Small Cell Lung Cancer (NSCLC) Market in 2025 here
News-ID: 3853868 • Views: …
More Releases from The Business Research Company
Global Self Healing Coatings Market Expansion at 21.1% CAGR, Valued at $8.13 Bil …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
What Are the Self Healing Coatings Market Size Forecast for 2025?
In recent years, the market size of self-healing coatings has witnessed tremendous growth. The forecast suggests an increase from $3.04 billion in 2024 to $3.78 billion in 2025, boasting an impressive compound annual growth rate (CAGR) of 24.3%. Several…
Phosgene Market on Path to Hit $6.25 Billion by 2029 at 5.2% CAGR
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Phosgene Market Outlook: What Size And CAGR Are Anticipated By 2025?
The size of the phosgene market has experienced substantial growth recently. It is anticipated to expand from $4.84 billion in 2024 to $5.1 billion in 2025, increasing at a compound annual growth rate (CAGR) of 5.5%. The rise experienced…
Future of Morpholine Market: Size, Share & Forecasts to 2029
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What Is the Projected Market Size Valuation of the Morpholine Market by 2025?
There has been an impressive expansion in the size of the morpholine market in the past few years. It's predicted to increase to $4.3 billion in 2025 from $4.04 billion in 2024, with a compound annual growth rate…
Industrial Catalyst Market Size to Reach $30.95 Billion by 2029 | Growth at 3.9% …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What is the Projected Market Size of the Industrial Catalyst Industry?
The size of the industrial catalyst market has shown consistent growth over the recent years. The market is expected to expand from $25.47 billion in 2024 to $26.59 billion in 2025, indicating a compound annual growth rate (CAGR) of 4.4%.…
More Releases for NSCLC
NSCLC Treatment Market Size, Drugs, Emerging Therapies and Companies 2032 | Delv …
DelveInsight's "NSCLC Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the NSCLC, historical and forecasted epidemiology as well as the NSCLC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Explore the intricate details of the NSCLC Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive NSCLC Market Forecast. Click here to stay ahead in healthcare…
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical…
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants.
Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904
Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,…
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail…
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot:
NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit…
Global cancer immunotherapies Market 2016:Melanoma, Prostate cancer, NSCLC
Cancer Immunotherapies has brought an unprecedented change in the global cancer therapies market. Cancer immunotherapy can be defined as, the treatment that deploys the bodys immune system, by joining and boosting innate powers of the immune system to fight cancer.
Over the past few years, cancer immunotherapies have generated new waves of optimism in the global oncology market, unveiling huge untapped potential for the innovators. After years of jostling over how…
